Fintel reports that on January 28, 2026, Barclays initiated coverage of Insmed (NasdaqGS:INSM) with a Overweight recommendation.
Analyst Price Forecast Suggests 39.76% Upside
As of January 14, 2026, the average one-year price target for Insmed is $217.87/share. The forecasts range from a low of $158.57 to a high of $253.05. The average price target represents an increase of 39.76% from its latest reported closing price of $155.89 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Insmed is 627MM, an increase of 40.31%. The projected annual non-GAAP EPS is -3.54.
What is the Fund Sentiment?
There are 1,130 funds or institutions reporting positions in Insmed. This is an decrease of 66 owner(s) or 5.52% in the last quarter. Average portfolio weight of all funds dedicated to INSM is 0.54%, an increase of 7.50%. Total shares owned by institutions decreased in the last three months by 3.30% to 252,156K shares. 
The put/call ratio of INSM is 0.53, indicating a bullish outlook.
What are Other Shareholders Doing?
Jpmorgan Chase holds 23,048K shares representing 10.81% ownership of the company. In its prior filing, the firm reported owning 15,636K shares , representing an increase of 32.16%. The firm increased its portfolio allocation in INSM by 93.24% over the last quarter.
Darwin Global Management holds 20,457K shares representing 9.59% ownership of the company. In its prior filing, the firm reported owning 19,345K shares , representing an increase of 5.44%. The firm decreased its portfolio allocation in INSM by 0.26% over the last quarter.
Capital International Investors holds 7,554K shares representing 3.54% ownership of the company. In its prior filing, the firm reported owning 7,479K shares , representing an increase of 0.99%. The firm increased its portfolio allocation in INSM by 35.47% over the last quarter.
Price T Rowe Associates holds 6,931K shares representing 3.25% ownership of the company. In its prior filing, the firm reported owning 11,231K shares , representing a decrease of 62.02%. The firm decreased its portfolio allocation in INSM by 16.59% over the last quarter.
Baker Bros. Advisors holds 6,703K shares representing 3.14% ownership of the company. In its prior filing, the firm reported owning 7,713K shares , representing a decrease of 15.06%. The firm decreased its portfolio allocation in INSM by 7.37% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
